Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated
about
PALB2: research reaching to clinical outcomes for women with breast cancerIs it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Gastrointestinal tract cancers: Genetics, heritability and germ line mutationsGenetic predisposition to pancreatic cancer.Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada.Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer casesPrevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE studyACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromesInternational Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancerPALB2 and breast cancer: ready for clinical translation!Risk factors and therapeutic targets in pancreatic cancer.Screening and early detection of pancreatic cancer in high risk population.Germline mutations in Japanese familial pancreatic cancer patients.Familial pancreatic cancer--current knowledge.Familial pancreatic cancer--status quo.The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview
P2860
Q26751309-C8C97CE0-42B0-4607-8167-A437D1043BB2Q28073673-2F174B87-84E1-4496-8BA3-4D5EF65CC845Q33599436-0046F3F9-03BC-42B9-9200-D854E49E5205Q34067868-7940F2A7-173D-446F-AA1D-3B24C2EFEF31Q34093790-2E6AA3C4-8574-4BAD-86CC-EC6280BA49BCQ34178875-66768D19-6B81-4B9A-9EAF-9216632D20F8Q34917808-DACADFB9-745B-4A97-B636-F480B9A57C1EQ35118758-1E8EE741-9DD3-42DD-9215-3629919E7CD3Q35630278-6406D12F-BE77-4529-AC21-C4045F7FA683Q36416282-1B552590-CF97-4262-875B-E79036D7B91DQ36648118-5B9BC30F-A390-45CB-9D35-B387DBB518DBQ37074279-A06C61C1-1E78-4DEF-8108-8A4150C0C18AQ37317310-EE9B8689-8D2E-4B07-BE2B-537A77240CFAQ37617979-B3314635-FE78-4144-81B6-0ECDE36771FCQ37687547-C0E48FF9-B3E8-48D4-9455-8AC4D1975CC2Q38016055-FE463975-CBCC-499E-A434-6433223C5EDEQ38129237-FE306053-01C7-421B-A3C3-D85981C42F59Q40063188-2E487825-141D-486C-A3EA-26C0495D278BQ57091632-E3670412-3787-43C3-B350-BD850CB70453
P2860
Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Routine testing for PALB2 muta ...... reatic cancer is not indicated
@ast
Routine testing for PALB2 muta ...... reatic cancer is not indicated
@en
type
label
Routine testing for PALB2 muta ...... reatic cancer is not indicated
@ast
Routine testing for PALB2 muta ...... reatic cancer is not indicated
@en
prefLabel
Routine testing for PALB2 muta ...... reatic cancer is not indicated
@ast
Routine testing for PALB2 muta ...... reatic cancer is not indicated
@en
P2093
P2860
P50
P356
P1476
Routine testing for PALB2 muta ...... reatic cancer is not indicated
@en
P2093
Anja Wagner
Cora M Aalfs
Femme Harinck
Maran Olderode-Berends
Marco J Bruno
Rolf H Sijmons
Saskia E van Mil
Theo A M van Os
P2860
P2888
P304
P356
10.1038/EJHG.2011.226
P577
2011-12-14T00:00:00Z